pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Aug 11·1 min read
save

Nonprofit North Star Review Board offers independent model to fix IRB oversight issues

Aug 11, 2026·read at STAT ↗RegulatoryNeutral

Founders Stephen Rosenfeld and Patricia Seymour created the not‑for‑profit North Star Review Board after becoming disillusioned with the current system of institutional review boards (IRBs) that oversee human research.

They argue that IRBs have drifted from their core mission of protecting research participants, citing a series of scandals over the past two decades that have eroded public trust.

A 2009 Government Accountability Office test highlighted a vulnerability when a for‑profit IRB approved a fabricated high‑risk device study, exposing how commercial pressures can compromise ethical review.

North Star proposes a nonprofit model intended to provide more independent oversight, aiming to restore confidence in the ethical review process for researchers and sponsors alike.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “IRBs have a problem. Can North Star’s nonprofit model save it?”

read at STAT ↗
2,665 words · retrieved Aug 11
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
University of Minnesota2University of Pennsylvania2Johns Hopkins UniversityMoonLake ImmunotherapeuticsNOVARTISNational Institutes of HealthRISINGROCHE
topics
Oncology3AsthmaCRO/CDMOCardiologyCystic FibrosisGene Therapy (AAV)Heart Failure

related stories

  • 1d agoNovo workforce down 13,000BioSpace
  • Sep 14After a brief storm of political headwinds, mRNA is back with strong momentumBioSpace
  • Dec 22Fierce Biotech Fundraising Tracker '26: Sling reels in $123M; Circle gathers $92.5MFierce Biotech
  • Sep 11STAT+: Cancer drug shortages keep disrupting patient careSTAT
  • Sep 10STAT+: FDA expands Bayer lung cancer drug approvalSTAT